Company Overview and News

4
B2Gold Celebrates the Opening of the Solar Power Plant at its Otjikoto Mine in Namibia

2018-06-05 globenewswire
VANCOUVER, British Columbia, June 05, 2018 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX:BTO) (NYSE AMERICAN:BTG) (NSX:B2G) ("B2Gold" or the "Company") is pleased to announce that on May 29, 2018, the Company celebrated the official opening of the B2Gold Solar Plant at its Otjikoto Mine in Namibia.
BTO BTG

4
Oklo Resources commences auger drilling in west Mali

2018-05-28 proactiveinvestors.com.au
Oklo Resources Ltd (ASX:OKU) has commenced auger geochemical drilling at the Kouroufing Project in western Mali.
OKU BTO BTG

4
Oklo Resources’ high-grade hits support potential for large gold system at Dandoko in Mali

2018-05-16 proactiveinvestors.com.au
Oklo Resources Ltd (ASX:OKU) has received high-grade gold hits from the Seko prospect at its Dandoko project in Mali, supporting the potential for a large mineralised system.
OKU BTO BTG

13
B2Gold Reports Strong First Quarter 2018 Results; Significant Beat Against Budget for Cash Operating Costs and AISC and Dramatic Increase in Cash Flows from Operating Activities to $147 Million

2018-05-10 globenewswire
VANCOUVER, British Columbia, May 09, 2018 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX:BTO) (NYSE AMERICAN:BTG) (NSX:B2G) (“B2Gold” or the “Company”) is pleased to announce its operational and financial results for the first quarter of 2018. The Company previously released its gold production and gold revenue for the first quarter of 2018 (see news release dated 04/11/18). All dollar figures are in United States dollars unless otherwise indicated.
AULGF BTO BTG AU AGG

4
B2Gold Announces Positive Exploration Drill Results from Fekola North Extension Zone and Resource Infill Drilling

2018-04-18 globenewswire
VANCOUVER, B.C., April 18, 2018 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX:BTO) (NYSE AMERICAN:BTG) (NSX:B2G) (“B2Gold” or the “Company”) announces positive exploration drill results from the Fekola North Extension Zone extending gold mineralization to one kilometer north of the Fekola Reserve pit boundary and continuing successful resource infill drilling.
BTO BTG

4
B2Gold Reports Record First Quarter Gold Production and Revenue in 2018; Quarterly Gold Production Increase of 81% to 240,000 Ounces and Revenues More than Double to $344 Million

2018-04-11 globenewswire
VANCOUVER, British Columbia, April 11, 2018 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX:BTO) (NYSE AMERICAN:BTG) (NSX:B2G) (“B2Gold” or the “Company”) is pleased to announce its gold production and gold revenue for the first quarter of 2018. All dollar figures are in United States dollars unless otherwise indicated.
BTO BTG

4
B2Gold has filed its Form 40-F

2018-03-23 globenewswire
VANCOUVER, British Columbia, March 23, 2018 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX:BTO) (NYSE AMERICAN:BTG) (NSX:B2G) (“B2Gold” or the “Company”) has filed with the U.S. Securities and Exchange Commission (the “SEC”) its SEC Annual Report on Form 40-F for the year ended December 31, 2017. The Form 40-F was filed on Friday, March 23, 2018. This includes the Company’s Annual Information Form, audited Financial Statements and Management’s Discussion & Analysis for the year ended December 31, 2017.
BTO BTG

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:BTO / B2Gold Corp. on message board site Silicon Investor.

BTOO - Biometrics 2000 Corporation BTOR Extreme Sports.
First Sierra Financial (BTOB) BTOB, the Internet-enabled Business to Business Bank
AMGV is Wal-Marts online BTO Vendor